首页> 美国卫生研究院文献>Federal Practitioner >Skeletal-Related Events in Patients With Multiple Myeloma and Prostate Cancer Who Receive Standard vs Extended-Interval Bisphosphonate Dosing

【2h】

Skeletal-Related Events in Patients With Multiple Myeloma and Prostate Cancer Who Receive Standard vs Extended-Interval Bisphosphonate Dosing

机译：接受标准与延长间隔双膦酸盐治疗的多发性骨髓瘤和前列腺癌患者的骨骼相关事件

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

In patients with multiple myeloma and prostate cancer, extending the bisphosphonate dosing interval may help decrease medication-related morbidity without compromising therapeutic benefit.

机译：在患有多发性骨髓瘤和前列腺癌的患者中，延长双磷酸盐的给药间隔可以帮助减少与药物相关的发病率，而不会影响治疗效果。

著录项

期刊名称 Federal Practitioner
作者
Abigail Shell; Leigh Anne Keough; Kothanur Rajanna;
展开▼
作者单位

展开▼
年(卷),期 2019(36),Suppl 1
年度 2019
页码 S22–S26
总页数 5
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study [J] . Yeon-Hee Baek, Ha-Lim Jeon, In-Sun Oh, Cancer epidemiology . 2019,第期

机译：乳腺癌或前列腺癌癌骨转移或多发性骨髓瘤患者的骨骼相关事件发生率：12年纵向全国保健数据库研究
2. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. [J] . Swaminathan P Iyer, Joseph Taddeus Beck, A Keith Stewart, British Journal of Haematology . 2014,第3期

机译：BHQ880结合抗骨髓瘤治疗和唑来膦酸的IB期多中心剂量测定研究，用于复发或难治性多发性骨髓瘤及先前骨骼相关事件的患者。
3. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. [J] . Swaminathan P Iyer, Joseph Taddeus Beck, A Keith Stewart, British Journal of Haematology . 2014,第3期

机译：BHQ880结合抗骨髓瘤治疗和唑来膦酸的IB期多中心剂量测定研究，用于复发或难治性多发性骨髓瘤及先前骨骼相关事件的患者。
4. The Risk for Secondary Cancers in Patients Treated for Prostate Carcinoma - An Analysis with the Competition Dose Response Model [C] . A. Dasu, I. Toma-Dasu, L. Franzen, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：前列腺癌患者继发癌症的风险-竞争剂量反应模型的分析
5. A comparative study of quality of life in patients with low-and intermediate-risk prostate cancer treated at a single institution: Stereotactic radiotherapy vs. high dose-rate brachytherapy monotherapy vs. high dose-rate brachytherapy boost [D] . Helou, Joelle. 2017

机译：单一机构治疗的中低危前列腺癌患者生活质量的比较研究：立体定向放疗与高剂量率近距离放射疗法单药疗法与高剂量率近距离放射疗法增强
6. What is the relationship between bone turnover markers and skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma? A systematic review and meta-regression analysis [O] . Zefei Jiang, En-Tzu Tang, Chuang Li, 2020

机译：实体瘤骨转移患者和多发性骨髓瘤患者的骨转换标志与骨骼相关事件之间有什么关系？系统评价和元回归分析
7. BISPHOSPHONATES IN PROPHYLAXIS OF SKELETAL-RELATED ADVERSE EVENTS IN PATIENTS WITH CASTRATION-REFRACTORY PROSTATE CANCER [O] . E. Yu. Safronova, S. A. Sergienko, A. S. Kalpinskiy, 2016

机译：双膦酸盐在阉割 - 难治性前列腺癌患者中骨骼相关不良事件的预防

Skeletal-Related Events in Patients With Multiple Myeloma and Prostate Cancer Who Receive Standard vs Extended-Interval Bisphosphonate Dosing

摘要

著录项

相似文献

相关主题

期刊订阅